Market Trends of Cytomegalovirus Treatment Industry
This section covers the major market trends shaping the Cytomegalovirus Treatment Market according to our research experts:
Stem Cell Transplantation Segment is Expected to Hold the Substantial Share in the Market During the Forecast Period
Stem cell transplantation is poised to benefit from the inclusion of new cell types, providing substantial opportunities for companies to reinforce their market position. As a result, the number of companies involved in cell therapy development has increased tremendously over the past years. Rising funding from the government and private organizations to support stem cell therapy clinical trials, the introduction of effective guidelines for stem cell therapy manufacturing, and the proven effectiveness of products are expected to be some of the primary growth drivers for the market segment.
As per the Springer study published in July 2021, CMV cell-mediated immunity assays have the potential to be used as an adjunctive test to develop an individualized management plan by identifying the patients who develop immune reconstitution. Maribavir and adoptive T-cell therapy are promising new therapies for treating CMV infections. CMV vaccine trials for prevention are also underway. Thus, the segment is expected to witness robust growth over the forecast period.
Moreover, the rising product approvals by various regulatory authorities are also expected to contribute to the market's growth. For instance, in September 2022, Health Canada authorized (Notice of Compliance) Takeda's LIVTENCITY (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies and individuals who have had a solid organ transplant or a hematopoietic stem cell transplant.
North America is Expected to Hold Notable Share of the Market Over the Forecast Period
North America is projected to hold a significant share of the global market throughout the forecast period. The increasing incidences of cytomegalovirus infections, increasing awareness among consumers, and the presence of key market players are some of the factors expected to play a crucial role in the market's growth in this region.
For instance, the article published by NINDS in July 2022 mentioned that CMV infected about 50% to 80% of adults by the age of 40 and is one of the most congenital infections in the United States annually. Similarly, the CMV Canada data published in June 2021, mentioned that one in 200 Canadian infants is infected with CMV during pregnancy. The report also mentioned that 1 in 5 congenital CMV had a permanent disability such as hearing loss or developmental delay. On the other hand, the BMC article published in September 2022, mentioned that seroprevalence of CMV infection in pregnant women in Mexico was higher in those aged 30 to 30 years (86.5%) than those aged less than 20 years in 2021. Such an increased incidence of CMV among the North American population is expected to contribute to the higher demand for effective treatment, thereby driving the growth of the market.
Likewise, the rising product approvals to provide safe and effective treatments to patients are also expected to drive the market's growth during the forecast period. For instance, in November 2021, Takeda pharmaceutical received FDA approval for the product, Maribavir for the treatment of adults and pediatric patients aged 12 years or older with post-transplant cytomegalovirus infection/disease that is refractory to treatment.
Hence, the rising prevalence of CMV infections, the presence of key market players, and frequent product developments are expected to drive the market's growth over the forecast period in this region.
